Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS6 in pregnant women with and without HIV
NCT05832502Phase 2Unknown
- Sponsor
- St George's, University of London
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GBS6 in group B streptococcal infection (4 arms), sponsored by St George's, University of London. Primary endpoints: Primary mother outcome 1-4 (Safety) and Primary Infant outcome 1-2 (Safety) at 12 months. Status: unknown.
02
Drugs
GBS6
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT05832502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832502.